Sanofi Announces Soliqua 100/33 Now Available in the U.S. Paris, France

Sanofi Announces Soliqua 100/33 Now Available in the U.S.

Paris, France January 4, 2017 Sanofi announced today that Soliqua 100/33 (insulin

glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2

diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.

We are encouraged by

the potential of Soliqua 100/33, which has demonstrated superior HbA1c lowering versus Lantus, said Peter Guenter, Executive Vice President, Head,

Global Diabetes & Cardiovascular Business Unit, Sanofi. By offering Soliqua 100/33 a product containing both a basal insulin and

a GLP-1 therapy at a competitive price while facilitating patient access, we believe we

are providing value to patients and the healthcare system.

In the labeled clinical

trial, once-daily Soliqua 100/33 demonstrated statistical superiority for the change in HbA1c from baseline to week 30 (p<0.0001) versus Lantus , the most prescribed basal insulin in the

world.1,2,3 The most common side effects reported in the clinical program included low blood sugar, nausea, stuffy or runny nose and sore throat, diarrhea, upper respiratory tract infection and

headache. Soliqua 100/33 is delivered in a single pre-filled SoloStar pen with a dose range covering from 15 to 60 Units and two starting doses to support patients insulin needs. Soliqua 100/33 was

approved by the U.S. Food and Drug Administration (FDA) on November 21, 2016.

The daily Wholesale Acquisition Cost (WAC) price of Soliqua 100/33 is

$127 for a 300 Unit pen, which equals $19.90 per day at the average final dose of 47 Units used in the labeled clinical trial.

Sanofi is offering Soliqua

100/33 at a $0 co-pay** for eligible U.S. patients with commercial insurance and is working to secure coverage for Soliqua 100/33 on health plans

nationwide. Sanofi is also offering a tailored support program, Soliqua 100/33 COACH, at no cost to adults living with type 2 diabetes who have been prescribed Soliqua 100/33 by their doctor. For additional information, please visit www.soliqua100-33.com.

Healthcare professionals need a broad range of treatments to individualize a

patient s diabetes care, particularly for the many adults living with diabetes who continue to face challenges in controlling their blood sugar levels even after treatment with basal insulin, said George Grunberger, M.D., FACP, FACE,

Chairman, Grunberger Diabetes Institute. This combination product provides a new option for many patients uncontrolled on basal insulin therapy or lixisenatide.

What is SOLIQUATM 100/33 (insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL injection)?

SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine 100 Units/mL and lixisenatide, that may

improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide.

Important Safety Information for SOLIQUATM 100/33 (insulin glargine and lixisenatide injection) 100

Units/mL and 33 mcg/mL

What is the most important information I should know about SOLIQUA 100/33?

Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be life-threatening.

Before using SOLIQUA 100/33, tell your doctor if you have had:

These medical problems may make you more likely to get pancreatitis. Stop taking SOLIQUA 100/33 and call your healthcare

provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?

100/33 if you are having an episode of low blood sugar (hypoglycemia) or if you are allergic to insulin glargine, lixisenatide, or any of the other ingredients in SOLIQUA 100/33.

Tell your healthcare provider about all your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including all

prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work

How should I use SOLIQUA 100/33?

SOLIQUA 100/33 may cause serious side effects, including:

The most common side effects of SOLIQUA 100/33 may include:

Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

Please click here for full Prescribing Information for SOLIQUA 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL:

www.soliqua100-33.com.

About Sanofi Diabetes & Cardiovascular

Diabetes and cardiovascular disease affect millions of people worldwide, with many managing the complex challenges of both. Building on our portfolio

evolution, heritage and expertise, Sanofi has a focused business unit dedicated to delivering innovative, value-based medicines and integrated

solutions in these therapeutic areas. We are committed to a collaborative approach that involves strategic alliances with professional and patient associations, research institutions and leaders

in healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and technology, helping to improve outcomes and inspiring an evolution in care.

Sanofi, a global healthcare leader,

discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and

Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product.

Forward-looking statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans , looks forward and similar expressions.

Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties,

many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and

statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee

that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety,

quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or

identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.